PMID- 27362768
OWN - NLM
STAT- MEDLINE
DCOM- 20170320
LR  - 20200106
IS  - 2299-5684 (Electronic)
IS  - 1734-1140 (Linking)
VI  - 68
IP  - 5
DP  - 2016 Oct
TI  - Molecular targets of metformin antitumor action.
PG  - 918-25
LID - S1734-1140(16)30039-1 [pii]
LID - 10.1016/j.pharep.2016.04.021 [doi]
AB  - Epidemiological studies have shown that metformin, a first line therapeutic agent 
      for diabetes mellitus, reduced the risk of developing various malignancies. 
      Several preclinical studies established some possible mechanisms of its 
      anticancer effects. The primary effect of metformin action is a decrease in cell 
      energy status, which activates AMP-activated kinase (AMPK), a cellular metabolic 
      sensor. This event is followed by a decrease in serum concentrations of insulin 
      and insulin growth factor I (IGF-I), the potent mitogens for cancer cells. In 
      addition to the indirect mode of action, metformin may exhibit direct inhibitory 
      effect on cancer cells by targeting mammalian target of rapamycin (mTOR) 
      signaling and anabolic processes. This review gathers information on mechanisms 
      of metformin antitumor activity, with special attention given to the impact of 
      this antidiabetic drug on insulin/PI3K/mTOR and AMPK signaling. Furthermore, the 
      factors required for this novel activity of metformin are discussed.
CI  - Copyright (c) 2016 Institute of Pharmacology, Polish Academy of Sciences. Published 
      by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
FAU - Sosnicki, Stanislaw
AU  - Sosnicki S
AD  - School of Pharmacy with the Division of Laboratory Medicine in Sosnowiec, Medical 
      University of Silesia, Katowice, Poland, Department of Biochemistry, Sosnowiec, 
      Poland. Electronic address: ssosnicki88@gmail.com.
FAU - Kapral, Malgorzata
AU  - Kapral M
AD  - School of Pharmacy with the Division of Laboratory Medicine in Sosnowiec, Medical 
      University of Silesia, Katowice, Poland, Department of Biochemistry, Sosnowiec, 
      Poland. Electronic address: mkapral@sum.edu.pl.
FAU - Weglarz, Ludmila
AU  - Weglarz L
AD  - School of Pharmacy with the Division of Laboratory Medicine in Sosnowiec, Medical 
      University of Silesia, Katowice, Poland, Department of Biochemistry, Sosnowiec, 
      Poland. Electronic address: lweglarz@sum.edu.pl.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160509
PL  - Switzerland
TA  - Pharmacol Rep
JT  - Pharmacological reports : PR
JID - 101234999
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology/*therapeutic use
MH  - Drug Delivery Systems/methods
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology/therapeutic use
MH  - Metformin/*pharmacology/*therapeutic use
MH  - Molecular Targeted Therapy/methods
MH  - Neoplasms/*drug therapy
MH  - Signal Transduction/drug effects
OTO - NOTNLM
OT  - Antitumor properties
OT  - Metformin
OT  - Molecular mechanisms
EDAT- 2016/07/01 06:00
MHDA- 2017/03/21 06:00
CRDT- 2016/07/01 06:00
PHST- 2016/03/18 00:00 [received]
PHST- 2016/04/29 00:00 [revised]
PHST- 2016/04/29 00:00 [accepted]
PHST- 2016/07/01 06:00 [entrez]
PHST- 2016/07/01 06:00 [pubmed]
PHST- 2017/03/21 06:00 [medline]
AID - S1734-1140(16)30039-1 [pii]
AID - 10.1016/j.pharep.2016.04.021 [doi]
PST - ppublish
SO  - Pharmacol Rep. 2016 Oct;68(5):918-25. doi: 10.1016/j.pharep.2016.04.021. Epub 
      2016 May 9.